Pulmonx (LUNG) to Release Earnings on Wednesday

Pulmonx (NASDAQ:LUNG) will likely be issuing its Q2 2026 results after the market closes on Wednesday, July 29th. Analysts expect Pulmonx to announce earnings of ($0.28) per share and revenue of $22.3940 million for the quarter. Parties may review the information on the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Wednesday, July 29, 2026 at 4:30 PM ET.

Pulmonx (NASDAQ:LUNG) last released its earnings results on Wednesday, April 29th. The company reported ($0.33) earnings per share for the quarter, hitting the consensus estimate of ($0.33). The firm had revenue of $20.59 million during the quarter, compared to analysts’ expectations of $20.43 million. Pulmonx had a negative return on equity of 92.94% and a negative net margin of 60.09%. On average, analysts expect Pulmonx to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Pulmonx Trading Up 4.3%

Shares of LUNG stock opened at $1.22 on Tuesday. Pulmonx has a fifty-two week low of $1.13 and a fifty-two week high of $3.39. The stock’s fifty day moving average price is $1.42 and its two-hundred day moving average price is $1.48. The company has a debt-to-equity ratio of 0.81, a quick ratio of 4.04 and a current ratio of 4.91. The company has a market cap of $51.53 million, a PE ratio of -0.94 and a beta of 0.30.

Institutional Investors Weigh In On Pulmonx

Large investors have recently modified their holdings of the company. ExodusPoint Capital Management LP bought a new position in Pulmonx during the fourth quarter worth $4,312,000. Vestal Point Capital LP bought a new stake in Pulmonx during the third quarter valued at $1,345,000. State Street Corp boosted its position in Pulmonx by 3.6% during the fourth quarter. State Street Corp now owns 821,217 shares of the company’s stock valued at $1,815,000 after acquiring an additional 28,813 shares during the last quarter. Bank of America Corp DE grew its holdings in Pulmonx by 556.6% during the 2nd quarter. Bank of America Corp DE now owns 481,268 shares of the company’s stock worth $1,246,000 after acquiring an additional 407,971 shares during the period. Finally, Barclays PLC grew its holdings in Pulmonx by 39.0% during the 4th quarter. Barclays PLC now owns 472,251 shares of the company’s stock worth $1,044,000 after acquiring an additional 132,569 shares during the period. 91.04% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on LUNG shares. D. Boral Capital reissued a “buy” rating and issued a $14.00 target price on shares of Pulmonx in a report on Thursday, April 30th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Pulmonx in a report on Monday, July 13th. Finally, Wall Street Zen upgraded Pulmonx from a “sell” rating to a “hold” rating in a research report on Saturday, June 27th. Four equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Pulmonx presently has a consensus rating of “Hold” and a consensus price target of $5.58.

Pulmonx Company Profile

Pulmonx Corporation is a commercial-stage medical device company focused on bronchoscopic lung volume reduction for patients suffering from severe emphysema. The company’s flagship therapy, the Zephyr® Endobronchial Valve System, employs one-way valves delivered via a minimally invasive bronchoscopic procedure to collapse diseased portions of the lung, reducing hyperinflation and improving respiratory function. Complementing this treatment, Pulmonx offers the Chartis® Pulmonary Assessment System, which provides clinicians with quantitative measurements of collateral ventilation to aid in patient selection and optimize clinical outcomes.

The Zephyr Valve received the CE mark in Europe in 2008 and FDA approval in the United States in 2018, and it has since been adopted by leading respiratory and thoracic centers across North America and Europe.